Request Demo
Last update 18 Oct 2025
Semaglutide biosimilar(Jiuyuan Gene)
Last update 18 Oct 2025
Overview
Basic Info
Drug Type Recombinant polypeptide, Biosimilar |
Synonyms JY29-2, 吉优泰, 吉可亲 |
Target |
Action agonists |
Mechanism GLP-1R agonists(Glucagon-like peptide 1 receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhaseNDA/BLA |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Sequence Code 50953
The sequence is quoted from: *****
Related
5
Clinical Trials associated with Semaglutide biosimilar(Jiuyuan Gene)CTR20244724
评价司美格鲁肽注射液与原研司美格鲁肽注射液在中国肥胖受试者中安全性和有效性的多中心、随机、开放、平行对照的III期临床研究
[Translation] A multicenter, randomized, open, parallel-controlled phase III clinical study to evaluate the safety and efficacy of semaglutide injection and original semaglutide injection in obese Chinese subjects
NCT06633783
A Multicenter, Randomized, Open-label, Parallel-controlled Phase III Study Comparing the Efficacy and Safety of Semaglutide Injection and Wegovy® for Weight Loss in Obese Subjects
ChiCTR2400089682
A randomized, open-label, single-dose, parallel-controlled phase I clinical trial comparing the pharmacokinetic similarity, safety, and immunogenicity of semaglutide injection and Ozempic ® injection in healthy subjects.
100 Clinical Results associated with Semaglutide biosimilar(Jiuyuan Gene)
Login to view more data
100 Translational Medicine associated with Semaglutide biosimilar(Jiuyuan Gene)
Login to view more data
100 Patents (Medical) associated with Semaglutide biosimilar(Jiuyuan Gene)
Login to view more data
100 Deals associated with Semaglutide biosimilar(Jiuyuan Gene)
Login to view more data
External Link
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Diabetes Mellitus, Type 2 | NDA/BLA | China | 03 Apr 2024 | |
| Obesity | Phase 3 | China | 21 Oct 2024 | |
| Cardiovascular Diseases | Phase 3 | China | 25 Jul 2022 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free